Genentech/Roche has a deep interest and investment in Personalized Healthcare to bring novel solutions to patients with retinal diseases. We are applying machine learning and advanced analytics on advanced imaging and high quality data at scale, initially derived from our vast clinical trial database. This wealth of longitudinal, multimodal data has been annotated, integrated and curated so that machine learning tools can be utilized in the effort to develop new insights in to retinal disease and treatment response to bring benefit to patients. We will collect additional data from our ongoing phase 3 programs as well as through significant collaborations and partnerships. 

As part of the large Ophthalmology Personalized Healthcare Initiative, Roche/Genentech are developing A.I./Machine Learning tools, with the current focus on neovascular AMD and diabetic eye disease, to predict and prevent vision loss. These algorithms can be used by ophthalmologists to deliver more personalized healthcare solutions to patients with retinal disease. 

We are committed to the utilization of these tools and accompanying insights to discover new therapeutic targets and develop better treatment paradigms. We have specific interests in prediction of disease progression and response to therapy, and seek novel data inputs and well validated algorithms that will further individualized approaches to disease based on large scale data inputs. Our program is committed to evaluating clinical utility and demonstrating benefit to bring meaningful change to patient care and outcomes. For more information about Personalized Healthcare at Roche, please visit our website.